E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Invasive Mycoses |
Micosis invasoras |
|
E.1.1.1 | Medical condition in easily understood language |
Severe fungal infections |
Infecciones graves por hongos |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective of this trial is to describe and compare the plasma-level pharmacokinetic profile of two oral formulations of posaconazole, oral suspension and solid tablets, administered sequentially to the same subjects |
El objetivo principal de este estudio es describir el perfil farmacocinético del posaconazol a nivel plasmático de manera comparada entre la suspensión oral y los comprimidos gastrorresistentes, administradas de manera secuencial en los mismos sujetos. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of the study are to evaluate the gastrointestinal tolerability and treatment experience with both formulations for the patient, to evaluate laboratory safety results and to describe any potential episodes of breakthrough invasive mycosis that may occur during the study treatment. |
Los objetivos secundarios del estudio son evaluar la tolerabilidad gastrointestinal y experiencia de tratamiento para el paciente con ambas formulaciones, evaluar los resultados de seguridad de laboratorio, así como registrar cualquier episodio potencial de micosis invasora que pudiese ocurrir durante el tratamiento de estudio. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Adult patiens with an indication for antifungal prophylaxis with posaconazole for prolonged severe neutropenia after intensive chemotherapy for acute myeloid leukemia or myelodysplastic syndromes. |
Pacientes adultos con indicación de profilaxis antifúngica con posaconazol por neutropenia grave prolongada por quimioterapia intensiva para leucemia aguda mieloblástica o síndromes mielodisplásicos. |
|
E.4 | Principal exclusion criteria |
Excluded are patients with a history of invasive mycosis, recipients of allogeneic transplantation with or without graft-versus-host disease, with abnormal liver or renal function, prolonged QTc, ECOG >2, pregnant women, or those with some concomitant or previous treatments. |
Se excluyen pacientes con antecedentes de micosis invasora, receptores de trasplante alogénico con o sin enfermedad injerto contra receptor, con alteraciones de función hepática o renal, QTc alargado, con ECOG >2, embarazadas, o con determinados tratamientos previos o concomitantes |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary objective of the study is to compare the pharmacokinetic profile of posaconazole oral suspension and solid tablets when administered sequentially to the same subjects.
The pharmacokinetic variables are:
- Cmin: Minimal concentration
- Cmax: Maximal observed concentration
- Tmax: Time to Cmax
- AUC: Area under the concentration/time curve
- Cavg: AUC/dose interval |
El objetivo principal de este estudio es describir el perfil farmacocinético del posaconazol a nivel plasmático de manera comparada entre la solución oral y los comprimidos gastrorresistentes al administrar ambas formulaciones de manera secuencial en los mismos sujetos.
Las variables farmacocinéticas de valoración son:
- Cmin: Concentración mínima
- Cmax: Concentración máxima observada
- Tmax: Tiempo hasta Cmax
- AUC: Área bajo la curva de concentración/tiempo
- Cpro: AUC/intervalo de dosis |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Pharmacokinetic samples will be taken:
- Day 1 and 8 of treatment with both formulations on time 0, +2h, +8h, +24h.
- End of treatment, a trough sample before last dose of study treatment. |
Muestras de farmacocinética se obtendrán:
- Los días 1 y 8 de tratamiento con las dos formulaciones a tiempo 0, +2h, +8h, +24h.
- Al final de tratamiento, una muestra valle antes de la última dosis de tratamiento de estudio. |
|
E.5.2 | Secondary end point(s) |
The secondary objectives are to evaluate gastrointestinal tolerability and treatment experience for the subjects with both formulations, to evaluate laboratory toxicity, to register any potential episodes of breakthrough invasive mycosis during study treatment, and to do a final evaluation of survival after end of treatment. |
Los objetivos secundarios del estudio son evaluar la tolerabilidad gastrointestinal y experiencia de tratamiento para el paciente con ambas formulaciones, evaluar los resultados de seguridad de laboratorio, registrar cualquier episodio potencial de MI que pudiese ocurrir durante el tratamiento de estudio, y hacer una evaluación final de supervivencia tras el fin de tratamiento |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
In every study visit (daily in inpatients) and final evaluation 1 week after end of treatment. |
En cada visita de estudio (diaria en ingresados) y a la evaluación final 1 semana tras el fin de tratamiento. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Otra formulación del mismo fármaco |
Other formulation of the same medicinal product |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |